Scarica l'app Stockscreener
25.28
0.59%
-0.15
Pre-mercato:
25.24
-0.04
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.43
Aprire:
$25.59
Volume 24 ore:
51.28M
Relative Volume:
0.81
Capitalizzazione di mercato:
$143.73B
Reddito:
$62.79B
Utile/perdita netta:
$9.84B
Rapporto P/E:
14.74
EPS:
1.7156
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+1.53%
1M Prestazione:
-2.88%
6M Prestazione:
+0.16%
1 anno Prestazione:
-6.82%
Intervallo 1D:
$25.14
$25.81
Intervallo di 1 settimana:
$24.83
$26.00
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.28 | 144.59B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Does Pfizer (PFE) Offer Long Term Value After A 36% Three Year Share Price Slide - simplywall.st
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43 - simplywall.st
Pfizer's (NYSE:PFE) Dividend Will Be $0.43 - Yahoo Finance
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026? - Nasdaq
Is Pfizer Inc PFE stock undervalued historicallyQuarterly Earnings Report & Proven Capital Preservation Tips - moha.gov.vn
Thousands Sue Pfizer Over Claims That Birth Control Caused Brain Tumors - iHeart
PFIZER INC : UBS withdraws its Sell rating - MarketScreener
Alert from law firm on Pfizer Depo-Provera MDL trial date withdrawn - MarketScreener
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio - The Joplin Globe
This Could Be Key to Pfizer's Turnaround in 2026 - Finviz
Bayer takes Pfizer and BioNTech to court over COVID vaccines - MarketScreener
Pfizer’s Scottish RSV Maternal Vaccine Study: What Investors Should Watch - TipRanks
Pfizer's Gandsman Takes Zeno Post - O'Dwyer's PR
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk - ts2.tech
Vitiligo Market Set for Robust Expansion Through 2034, DelveInsight Reports | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech - The Globe and Mail
Pfizer needs more than obesity deal to drive growth post-2028, UBS says - Investing.com Canada
Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines - MarketScreener
Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure (NYSE:PFE) - Seeking Alpha
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties - Law360
Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
Bayer sues COVID vaccine makers over mRNA technology - Reuters
December Social Media Round-Up—2025 Highlights, YaoPharma Co., Ltd. Global Collaboration, and More - Pfizer
Is Pfizer (PFE) Offering Value After Recent Share Price Weakness? - Yahoo Finance
Pfizer Stock Plot Twist: Is This Big Pharma OG a Secret Comeback Play or Total Trap? - AD HOC NEWS
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Pfizer invested in this Peninsula biotech startup. Now they've cut a potentially big drug deal - The Business Journals
Cartography Biosciences And Pfizer To Collaborate On The Discovery Of Tumor-Selective Antigens - TradingView — Track All Markets
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens - Business Wire
Torray Investment Partners LLC Acquires 102,107 Shares of Pfizer Inc. $PFE - MarketBeat
Sulfasalazine Market Is Booming Worldwide 2026-2033 | Pfizer - openPR.com
Robeco Institutional Asset Management B.V. Has $290.44 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Phenobarbital Market See Incredible Growth 2025-2032 | Sanofi, Pfizer Inc., Novartis AG, H. Lundbeck A/S - openPR.com
Pfizer's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Gateway Investment Advisers LLC Lowers Stock Position in Pfizer Inc. $PFE - MarketBeat
Sleep Aids Market Booming with Rapid Growth Through 2033| Pfizer Inc., GSK plc, Sommetrics, Inc. - openPR.com
Pfizer’s 2026 Drug Price Reset Could Be A Game Changer For Pfizer (PFE) - simplywall.st
Pfizer (PFE) Stock: COVID-19 Revenue Decline Spurs Strategic Shift - parameter.io
Pfizer Inc. $PFE Position Cut by Commonwealth Equity Services LLC - MarketBeat
Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals - Finviz
Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Dividend Support - Yahoo! Finance Canada
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - Bluefield Daily Telegraph
Better dividend stock: Ford vs. Pfizer - MSN
D.A. Davidson & CO. Acquires 70,161 Shares of Pfizer Inc. $PFE - MarketBeat
Better Dividend Stock: Ford vs. Pfizer - Finviz
Daymark Wealth Partners LLC Sells 52,529 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Allen Wealth Management LLC - MarketBeat
Asset Management One Co. Ltd. Grows Position in Pfizer Inc. $PFE - MarketBeat
Capital Advisors Inc. OK Grows Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc Is On Clearance?! The Wild Truth Behind PFE’s Price Drop - AD HOC NEWS
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom - ts2.tech
Pfizer Ltd Is Having a Moment: Hype Stock or Just Hot Air? - AD HOC NEWS
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.46%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):